It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Trading under the symbol ‘MTSR’, the company said it plans to use the funds to advance its glucagon-like peptide-1 receptor agonist (GLP-1RA) asset MET-097i through a Phase III trial.

Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that ...

Trading under the symbol ‘MTSR’, the company said it plans to use the funds to advance its glucagon-like peptide-1 receptor agonist (GLP-1RA) asset MET-097i through a Phase III trial. MET-097i ...

The concentrations of adiponectin, low-density lipoprotein-cholesterol (LDL-c), total cholesterol (TC), glucagon-like peptide 1 (GLP-1 ... The circle˚ or the symbol * represents the outliers in the ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Company announcement - No. 2 / 2025 Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant clinical advancement across differentiated obesity pipeli ...

Reasons to buy Viking Therapeutics now It's hard to overstate the commercial success of drugs that reduce appetites by acting on glucagon-like peptide-1 (GLP-1) receptors. Sales of semaglutide ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline. Click for my LLY stock update.

Medications known as glucagon-like peptide 1 (GLP-1) receptor agonists are taking over the healthcare industry. While you may not be familiar with the term "GLP-1," I'd wager you'll recognize some ...